Bispecifics

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Gardiner Smith; Reiner Gentz, Ph.D.

Fab Biopharma

Female-Centric

Transforming Drug Development through a Female Perspective

Chia Chia Sun; William Freimuth, Ph.D., M.D.

Fab Biopharma

Developability

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Heonchang Lim

Samsung Biologics

Drug Delivery

Nanocarriers to Overcome the Blood–Brain Barrier (BBB)

Serene Lee

Nice Insight

Changing Roles

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Pharma's Almanac

Nice Insight API Report

Small Molecule API Discovery and Development Trends

April Stanley, MS MBA

Nice Insight

Digital Pathology

Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform

Nathan Buchbinder

Proscia

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

Julie Trulson, Ph.D.

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

Julie Trulson, Ph.D.

Translation

The Translational Index Score: Improving the Entire Drug Development Cycle

Jo Varshney, Ph.D., D.V.M.

CMC

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform

Wheeler Bio

Drug Development

Podcast: Insights from CDO Experts from Samsung Biologics

Jiyeon Lee; Hyelyoung Jang

Samsung Biologics

Retinal Disease

Pioneering Breakthroughs in Retinal Disease Treatment

David Alvaro, Ph.D.; David Zacks, M.D., Ph.D.; David Esposito

Pharma's Almanac

Failing Fast

Maximizing Resources and Potential for Success by Failing Fast

Nazar Elkarim, Ph.D.

Mikart